Print（PDF/79KB） May 13, 2020 Corporate

Sumitomo Dainippon Pharma Announces Change in Board of Directors

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) announced today that in its meeting held on May 13, 2020, the Board of Directors appointed the following candidate for new member of the Board of Directors.

Change in the Members of the Board of Directors (as of June 23, 2020)

• New Member of the Board of Directors

  Yoshiharu Ikeda (currently Senior Executive Officer)

  Note: The new member of the Board of Directors who will take office as of June 23, 2020 subject to the approval at the general shareholders' meeting scheduled for the same date.

(Reference)

Brief Personal History of candidate for new member of the Board of Directors

• Yoshiharu Ikeda (Mr.) 　　Birthdate: January 5, 1958

  April 1985	Joined the former Sumitomo Pharmaceuticals Co., Ltd.
  June 2009	Senor Director, Global Corporate Strategy
  June 2010	Executive Officer, the Company
  Jan. 2012	Executive Vice President, Sunovion Pharmaceuticals Inc.
  April 2016	Senior Executive Officer (up to the present)
  April 2020	Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Division; Technology Research & Development Division; Manufacturing Division Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit (up to the present)